Spots Global Cancer Trial Database for recurrent fallopian tube endometrioid adenocarcinoma

Every month we try and update this database with for recurrent fallopian tube endometrioid adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02839707	Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
A Study of FRaDCs for Ovarian Cancer	NCT05920798	Fallopian Tube ... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Multi-epitope F... Pembrolizumab Pheresis	18 Years -	Mayo Clinic
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy	NCT05295589	Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima...	Computed Tomogr... Copanlisib Hydr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy	NCT05295589	Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima...	Computed Tomogr... Copanlisib Hydr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	NCT04739800	Fallopian Tube ... Ovarian Seromuc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Low ... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim...	Biospecimen Col... Cediranib Malea... Computed Tomogr... Computed Tomogr... Durvalumab Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	NCT04034927	Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian High Gr... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Tremelimumab	18 Years -	National Cancer Institute (NCI)
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	NCT05231122	Ovarian Clear C... Platinum-Sensit... Recurrent Endom... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Anti-CD40 Agoni... Bevacizumab Pembrolizumab Quality-of-Life... Questionnaire A...	18 Years -	Roswell Park Cancer Institute

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: